ES2065336T3 - Peptidos terapeuticos. - Google Patents

Peptidos terapeuticos.

Info

Publication number
ES2065336T3
ES2065336T3 ES88308916T ES88308916T ES2065336T3 ES 2065336 T3 ES2065336 T3 ES 2065336T3 ES 88308916 T ES88308916 T ES 88308916T ES 88308916 T ES88308916 T ES 88308916T ES 2065336 T3 ES2065336 T3 ES 2065336T3
Authority
ES
Spain
Prior art keywords
site
union
analog
occurs naturally
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308916T
Other languages
English (en)
Inventor
David H Coy
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of ES2065336T3 publication Critical patent/ES2065336T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PEPTIDO LINEAL QUE ES UN ANALOGO DE LA BOMBESINA BIOLOGICAMENTE ACTIVO, QUE OCURRE NATURALMENTE QUE TIENE UN SITIO ACTIVO Y UN SITIO DE UNION RESPONSABLE DE LA UNION DE LA BOMBESINA AL RECEPTOR DE LA CELULA BLANCO, DIVISION DEL PEPTIDO LAZO EN EL SITIO ACTIVO DEL PEPTIDO QUE OCURRE NATURALMENTE SIENDO INNECESARIO PARA LA ACTIVIDAD BIOLOGICA IN VIVO. EL ANALOGO TIENE UN LAZO NO - PEPTIDO A CAMBIO DE UN PEPTIDO LAZO ENTRE UN AMINOACIDO DEL SITIO ACTIVO Y UN AMINOACIDO ADYACENTE, Y TIENE EL MISMO SITIO DE UNION QUE EL PEPTIDO QUE OCURRE NATURALMENTE, ASI QUE EL ANALOGO, ES CAPAZ DE ACTUAR COMO INHIBIDOR COMPETITIVO DE LA BOMBESINA QUE OCURRE NATURALMENTE POR UNION AL RECEPTOR, Y POR VIRTUAL DEL LAZO NO - PEPTIDO, FALTA DE EXHIBIR LA ACTIVIDAD IN VIVO DE LA BOMBESINA QUE OCURRE NATURALMENTE.
ES88308916T 1987-09-24 1988-09-26 Peptidos terapeuticos. Expired - Lifetime ES2065336T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10057187A 1987-09-24 1987-09-24

Publications (1)

Publication Number Publication Date
ES2065336T3 true ES2065336T3 (es) 1995-02-16

Family

ID=22280431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308916T Expired - Lifetime ES2065336T3 (es) 1987-09-24 1988-09-26 Peptidos terapeuticos.

Country Status (9)

Country Link
EP (1) EP0309297B1 (es)
JP (1) JP2795449B2 (es)
AT (1) ATE113961T1 (es)
DE (1) DE3852086T2 (es)
DK (1) DK249489A (es)
ES (1) ES2065336T3 (es)
FI (1) FI100719B (es)
NO (1) NO178306C (es)
WO (1) WO1989002897A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877277A (en) * 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
GB8808768D0 (en) * 1988-04-14 1988-05-18 Erba Carlo Spa Peptide ligands for bombesin receptors
GB8813356D0 (en) * 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
GB2231051B (en) * 1989-05-05 1992-12-16 Erba Carlo Spa Bombesin antagonists
IL96216A0 (en) * 1989-11-06 1991-08-16 Erba Carlo Spa Peptide derivatives,their preparation and pharmaceutical compositions containing them
NZ236114A (en) * 1989-11-22 1993-04-28 Merrell Dow Pharma Peptide antagonists of bombesin and of gastrin releasing peptide, and pharmaceutical compositions
US5834433A (en) * 1990-07-26 1998-11-10 Merrell Pharmaceuticals Inc. Compounds and pharmaceutical uses of peptides of bombesin and GRP
ZA915740B (en) * 1990-07-26 1992-05-27 Merrell Dow Pharma Peptides
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
AU659659B2 (en) * 1991-05-23 1995-05-25 Merrell Dow Pharmaceuticals Inc. Bombesin analogs
EP0626973A1 (en) * 1992-02-07 1994-12-07 Merrell Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US6492330B1 (en) 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US6156725A (en) * 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
EP0835662B1 (en) * 1996-10-08 2001-11-14 National Institute of Immunology A drug for the treatment of cancer
DK1165613T3 (da) 1999-03-29 2008-08-25 Procter & Gamble Melanocortinreceptorligander
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
US7922998B2 (en) 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7611692B2 (en) 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8420050B2 (en) 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
NZ564694A (en) 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム １８ｆ標識物質のための化合物と方法
CA2727082C (en) 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP2198878A1 (en) 2008-12-18 2010-06-23 University Of Miami Polypeptide bombesin antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207311A (en) * 1977-07-18 1980-06-10 The Salk Institute For Biological Studies Peptides having analgesic and thermoregulative properties

Also Published As

Publication number Publication date
DE3852086T2 (de) 1995-05-18
DE3852086D1 (de) 1994-12-15
DK249489D0 (da) 1989-05-23
NO892060L (no) 1989-07-21
JP2795449B2 (ja) 1998-09-10
EP0309297A2 (en) 1989-03-29
ATE113961T1 (de) 1994-11-15
JPH02502016A (ja) 1990-07-05
AU2710288A (en) 1989-04-18
FI892507A0 (fi) 1989-05-23
NO178306B (no) 1995-11-20
AU622123B2 (en) 1992-04-02
WO1989002897A1 (en) 1989-04-06
FI892507L (fi) 1989-05-23
NO178306C (no) 1996-02-28
NO892060D0 (no) 1989-05-23
DK249489A (da) 1989-07-20
FI100719B (fi) 1998-02-13
EP0309297B1 (en) 1994-11-09
EP0309297A3 (en) 1990-07-04

Similar Documents

Publication Publication Date Title
ES2065336T3 (es) Peptidos terapeuticos.
FI911780A0 (fi) Terapeutiska peptider.
ES2090140T3 (es) Peptidos terapeuticos.
ES2163864T3 (es) Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas.
PT720482E (pt) Prosaposina e peptidos derivados da citocina utilizados como agentes
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
SV2002000233A (es) Compuestos, composiciones y metodos para estimular el crecimiento y elongacion neuronal caso # 0081-01-sv
ES2196031T3 (es) Derivados peptidicos terapeutico.
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
BR9810336A (pt) Receptor quinase bin1
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
PE20230487A1 (es) Variantes de alfa-galactosidasa humana
ES2075893T3 (es) Activacion in vivo especifica de sede de farmacos terapeuticos.
ZA202405789B (en) Blood-brain barrier permeable fusion protein and uses thereof
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
ES8606401A1 (es) Un procedimiento para preparar peptidos
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
ES2094160T3 (es) Peptidos terapeuticos, en particular analogos del peptido substancia p.
AR020101A1 (es) Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
ES2001147A4 (es) Un procedimiento para la preparacion de una composicion farmaceutica que tiene actividad reguladora del calcio
ES2059717T3 (es) Nuevos polipeptidos y adn codante para estos.
SE9302414D0 (sv) Peptid med oxytocinantagonist-aktivitet
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 309297

Country of ref document: ES